1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow BGJ398: new trials by email Literature Review of BGJ398 trials Research Report on BGJ398
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations BGJ398, Gemcitabine, Cisplatin - Advanced Cholangiocarcinoma, FGFR2 Gene Mutation | Phase 3 | Terminated | QED Therapeutics, a BridgeBio company | 48 | 2019-12-27 | 2024-05-08 |
QED Therapeutics, a BridgeBio company (1)
Australia (1) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Italy (1) · Portugal (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Taiwan (1) · Thailand (1) · United Kingdom (1) · United States (1)
2018 (1)